IU receives $30 million for Alzheimer s, dementia research fordcountyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fordcountyrecord.com Daily Mail and Mail on Sunday newspapers.
IU School of Medicine wins $30 million NIA funding to study Alzheimer’s disease and related dementias
National Centralized Repository for Alzheimer s Disease and Related Dementias (NCRAD) grant has been renewed for another five years with funding expected to total $30 million from the National Institute on Aging (NIA), within the National Institutes of the Health (NIH). NCRAD is led by Tatiana Foroud, PhD, Executive Associate Dean for Research Affairs at IU School of Medicine. Since 2018, NCRAD has been among the five largest grants awarded to IU School of Medicine.
National Centralized Repository for Alzheimer s Disease and Related Dementias serves as the primary resource for samples for all NIA-funded dementia studies. In the next five years, our recruitment efforts will focus on engaging diverse communities to obtain a broad range of samples from individuals that represent the diversity of populations that make up our nation and our world.
Date Time
IU School of Medicine scientists discover ‘game-changer’ treatment for triple negative breast cancer
The new precision immunotherapy for triple negative breast cancer was developed from a mushroom toxin. Image courtesy of Xiongbin Lu
A team of Indiana University School of Medicine researchers has developed a novel antibody-drug conjugate for treating triple negative breast cancer.
The study, led by senior author Xiongbin Lu, Vera Bradley Foundation Professor of Breast Cancer Innovation at the IU School of Medicine, has been published in the prestigious interdisciplinary medical journal, Science Translational Medicine.
Triple negative breast cancer accounts for about 15 percent of all breast cancer cases. When a patient tests negative for estrogen receptors and progesterone receptors and has low levels of a protein called HER2, the patient is considered to have “triple negative” breast cancer. Patients with triple negative breast cancer typically have the poores
Researchers from Indiana University s Precision Health Initiative say they continue to move forward in an effort to revolutionize the way clinical trials are conducted around the world. Launched in 20
IU researchers identify how breast cancer cells evade immune attacks
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a protein called MAL2 on the cell surface, the cancer cells can evade immune attacks and continue to grow. The findings are published this month in
The Journal of Clinical Investigation and featured on the journal s cover.
The lead author of the study, Zhang is a member of the IU Simon Comprehensive Cancer Center and assistant professor of medical and molecular genetics at IU School of Medicine.